NICE recommends Erbitux for bowel cancer

2 March 2017
merckkgaa-big

Erbitux (cetuximab) is closer to being available on the UK’s National Health Service (NHS) as an option for RAS wild type metastatic colorectal cancer (mCRC).

In a final appraisal determination, the National Institute for Health and Care Excellence (NICE), the cost-effectiveness watchdog for England and Wales, has recommended this monoclonal antibody, from German pharma firm Merck KGaA (MRK: DE), for first-line treatment of adult patients with epidermal growth factor receptor (EGFR) who express mCRC, in combination with FOLFOX (5-fluorouracil, folinic acid and oxaliplatin) or FOLFIRI (5-fluorouracil, folinic acid and irinotecan).

More than 22,000 new cases of patients are diagnosed with late-stage or metastatic colorectal cancer in the UK each year and about half of these have RAS wild-type tumors.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical